Santhera Pharmaceuticals Holding AG (SANN.SW)
CHF 9.86
(2.49%)
CHF 9.86
(2.49%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 31.33 Million CHF | -12.27% |
| 2022 | 55.85 Million CHF | 8.41% |
| 2021 | 51.52 Million CHF | -10.63% |
| 2020 | 57.65 Million CHF | -28.26% |
| 2019 | 80.36 Million CHF | 2.54% |
| 2018 | 78.37 Million CHF | 13.11% |
| 2017 | 69.29 Million CHF | 43.53% |
| 2016 | 48.27 Million CHF | 79.6% |
| 2015 | 26.88 Million CHF | 171.28% |
| 2014 | 9.9 Million CHF | 16.74% |
| 2013 | 8.48 Million CHF | -75.29% |
| 2012 | 34.34 Million CHF | 13.95% |
| 2011 | 30.14 Million CHF | 4.14% |
| 2010 | 28.94 Million CHF | -39.69% |
| 2009 | 47.99 Million CHF | 5.2% |
| 2008 | 45.61 Million CHF | 6.6% |
| 2007 | 42.79 Million CHF | 42.37% |
| 2006 | 30.05 Million CHF | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 13.32 Million CHF | 0.0% |
| 2024 Q1 | 13.32 Million CHF | -50.58% |
| 2023 Q2 | 22.05 Million CHF | 153.24% |
| 2023 Q3 | 2.73 Million CHF | -87.6% |
| 2023 Q4 | 26.95 Million CHF | 885.56% |
| 2023 Q1 | 8.7 Million CHF | -55.39% |
| 2023 FY | 49 Million CHF | -12.27% |
| 2022 Q4 | 19.51 Million CHF | 33.88% |
| 2022 Q3 | 14.57 Million CHF | -50.79% |
| 2022 Q2 | 29.62 Million CHF | 135.54% |
| 2022 Q1 | 12.57 Million CHF | -57.45% |
| 2022 FY | 55.85 Million CHF | 8.41% |
| 2021 FY | 51.52 Million CHF | -10.63% |
| 2021 Q4 | 29.55 Million CHF | 174.1% |
| 2021 Q1 | 5.68 Million CHF | -75.52% |
| 2021 Q2 | 21.53 Million CHF | 278.84% |
| 2021 Q3 | 10.78 Million CHF | -49.93% |
| 2020 Q1 | 17.34 Million CHF | -58.21% |
| 2020 Q2 | 30.82 Million CHF | 77.69% |
| 2020 Q3 | 15.22 Million CHF | -50.61% |
| 2020 FY | 57.65 Million CHF | -28.26% |
| 2020 Q4 | 23.21 Million CHF | 52.5% |
| 2019 Q3 | 21.35 Million CHF | -42.71% |
| 2019 FY | 80.36 Million CHF | 2.54% |
| 2019 Q2 | 37.28 Million CHF | 88.61% |
| 2019 Q1 | 19.76 Million CHF | -6.67% |
| 2019 Q4 | 41.51 Million CHF | 94.37% |
| 2018 Q4 | 21.18 Million CHF | 22.34% |
| 2018 FY | 78.37 Million CHF | 13.11% |
| 2018 Q3 | 17.31 Million CHF | -13.19% |
| 2018 Q2 | 19.94 Million CHF | 0.0% |
| 2018 Q1 | 19.94 Million CHF | -8.6% |
| 2017 Q2 | 15.14 Million CHF | 0.0% |
| 2017 FY | 69.29 Million CHF | 43.53% |
| 2017 Q4 | 21.81 Million CHF | 26.82% |
| 2017 Q3 | 17.2 Million CHF | 13.61% |
| 2017 Q1 | 15.14 Million CHF | 17.26% |
| 2016 FY | 48.27 Million CHF | 79.6% |
| 2016 Q4 | 12.91 Million CHF | 0.0% |
| 2016 Q3 | 12.91 Million CHF | 14.76% |
| 2016 Q2 | 11.25 Million CHF | 0.0% |
| 2016 Q1 | 11.25 Million CHF | 199.88% |
| 2015 Q4 | 3.75 Million CHF | 0.0% |
| 2015 Q2 | 3.75 Million CHF | 0.0% |
| 2015 FY | 26.88 Million CHF | 171.28% |
| 2015 Q1 | 3.75 Million CHF | 15.53% |
| 2015 Q3 | 3.75 Million CHF | -0.09% |
| 2014 Q1 | 1.91 Million CHF | 61.02% |
| 2014 FY | 9.9 Million CHF | 16.74% |
| 2014 Q4 | 3.25 Million CHF | 0.0% |
| 2014 Q3 | 3.25 Million CHF | 69.46% |
| 2014 Q2 | 1.91 Million CHF | 0.0% |
| 2013 Q2 | 2.27 Million CHF | 0.0% |
| 2013 Q1 | 2.27 Million CHF | -81.87% |
| 2013 FY | 8.48 Million CHF | -75.29% |
| 2013 Q4 | 1.19 Million CHF | 0.0% |
| 2013 Q3 | 1.19 Million CHF | -47.51% |
| 2012 Q3 | 12.51 Million CHF | 0.0% |
| 2012 FY | 34.34 Million CHF | 13.95% |
| 2012 Q4 | 12.51 Million CHF | 0.0% |
| 2011 FY | 30.14 Million CHF | 4.14% |
| 2010 FY | 28.94 Million CHF | -39.69% |
| 2009 FY | 47.99 Million CHF | 5.2% |
| 2008 FY | 45.61 Million CHF | 6.6% |
| 2007 FY | 42.79 Million CHF | 42.37% |
| 2006 FY | 30.05 Million CHF | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Addex Therapeutics Ltd | 11.89 Million CHF | -163.447% |
| BB Biotech AG | -199.56 Million CHF | 115.701% |
| Basilea Pharmaceutica AG | 111.63 Million CHF | 71.931% |
| Evolva Holding SA | 89.66 Million CHF | 65.052% |
| Idorsia Ltd | 400.38 Million CHF | 92.174% |
| Kuros Biosciences AG | 36.21 Million CHF | 13.485% |
| Molecular Partners AG | 20.3 Million CHF | -54.344% |
| Relief Therapeutics Holding AG | 114.94 Million CHF | 72.738% |